切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2018, Vol. 12 ›› Issue (01) : 65 -70. doi: 10.3877/cma.j.issn.1674-1358.2018.01.013

所属专题： 文献；

临床论著

糖尿病合并不同临床表型肺部感染者的细菌谱分析
刘春妮1, 初卫江2, 高爱芹1, 饶小胖1,†()   
  1. 1. 266109　青岛市，山东省青岛市城阳区人民医院
    2. 261400　莱州市，山东省莱州市第三人民医院内分泌科
  • 收稿日期:2017-02-18 出版日期:2018-02-15
  • 通信作者: 饶小胖

Bacterial analysis of pulmonary infection in patients with diabetes mellitus complicated with different clinical phenotypes

Chunni Liu1, Weijiang Chu2, Aiqin Gao1, Xiaopang Rao1,†()   

  1. 1. People’s Hospital of Qingdao Chengyang District, 266109 Qingdao, China
    2. Department of Endocrinology, The Third People’s Hospital of Laizhou, 261400 Laizhou, China
  • Received:2017-02-18 Published:2018-02-15
  • Corresponding author: Xiaopang Rao
  • About author:
    Corresponding author: Rao Xiaopang, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

刘春妮, 初卫江, 高爱芹, 饶小胖. 糖尿病合并不同临床表型肺部感染者的细菌谱分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2018, 12(01): 65-70.

Chunni Liu, Weijiang Chu, Aiqin Gao, Xiaopang Rao. Bacterial analysis of pulmonary infection in patients with diabetes mellitus complicated with different clinical phenotypes[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2018, 12(01): 65-70.

目的

探讨糖尿病合并不同临床表现肺部感染者的细菌分布情况，有针对性地制定抗感染对策。

方法

根据208例糖尿病合并肺部感染者的不同临床表现分为呼吸道症状组（RS）、全身症状组（SS）及综合症状组（CS）共3组，取其痰分泌物进行病原学培养，培养菌株232株，统计学分析采用SPSS软件。

结果

CS组混合感染（19.13%）较RS组（4.00%）和SS组患者（11.39%）显著上升（χ2= 5.41，P=0.01）；RS组患者革兰阳性球菌（G+C）感染仅占20%，SS组患者G+C感染占69.6%，CS组患者G+C感染为33.9%（χ2= 9.90，P=0.001）；RS组患者革兰阴性杆菌（G－B）感染占76%，SS组患者G－B感染仅占25.3%，CS组患者G－B感染为59.3%（χ2= 14.87，P=0.001）；RS组患者葡萄球菌对莫西沙星、阿奇霉素、克林霉素、庆大霉素、左氧氟沙星、环丙沙星、四环素、青霉素、利福平、头孢呋辛和头孢唑肟耐药率显著低于SS组和CS组（P均< 0.05）。SS组患者链球菌对莫西沙星、阿奇霉素、克林霉素、四环素、头孢呋辛及头孢唑肟耐药率显著低于CS组（P均< 0.05）；SS组患者ECO对莫西沙星、庆大霉素及头孢唑肟耐药率显著低于CS组（P均< 0.05）；RS组患者肺炎克雷伯菌对亚胺培南、头孢哌酮舒巴坦、哌拉西林他唑巴坦、头孢吡肟、头孢噻汚、头孢他啶、头孢唑肟、庆大霉素、环丙沙星、左氧氟沙星、氨曲南和氨苄西林耐药率显著低于SS组和CS组患者（P均< 0.05）；RS组患者中铜绿假单胞杆菌和鲍曼/溶血不动杆菌对头孢哌酮舒巴坦、哌拉西林他唑巴坦、头孢吡肟、头孢噻汚、头孢他啶、头孢唑肟、庆大霉素、环丙沙星、左氧氟沙星、氨曲南及氨苄西林耐药率显著低于SS组和CS组患者（P均< 0.05）。

结论

糖尿病合并不同临床表型肺部感染患者的细菌谱分布存在差异；针对以上感染特点有助于指导临床进行抗感染治疗。

关键词: 糖尿病, 临床表型, 肺部感染, 细菌谱
Objective

To investigate the pathogenic conditions of pulmonary infection in patients with diabetes.

Methods

Total of 208 patients with diabetes complicated with pulmonary infection of different clinical manifestations were divided into three groups: respiratory symptoms group (RS group), systemic symptom group (SS group) and comprehensive syndrome group (CS group), and the pathogen of their sputum were cultured for 232 strains, and the statistical analysis was carried out by SPSS 16.0 software.

Results

Mixed infection (19.13%) in CS group was significantly higher than those of the RS group (4.00%) and the group SS (11.39%). In patients of the RS group, the infection rate of Gram positivecocci(G+C) was 20%, which were 69.6% in the SS group and 33.9% in the CS group, with significant difference (χ2= 9.90,P= 0.001). G-B infection rate of patients of the RS group was 76%, which were 25.3% in the SS group and 59.3% in the CS group, with significant difference (χ2 = 14.87,P= 0.001). The resistance rates ofStaphylococcusto moxifloxacin, azithromycin, clindamycin, gentamicin, erythromycin, levofloxacin, ciprofloxacin, tetracycline, penicillin, rifampicin, cefuroxime and ceftizoxime of the RS group were significantly lower than those of SS group and CS group (allP< 0.05). The resistance rates ofStreptococcusto azithromycin, moxifloxacin, clindamycin, erythromycin, tetracycline, cefuroxime and ceftizoxime in the SS group were significantly lower than those of the CS group (allP< 0.05). The resistance rates ofEnterococcusto moxifloxacin, gentamicin and ceftizoxime in patients of the SS group were significantly lower than those of in the CS group (allP< 0.05). In patients of the RS group, the resistance rates ofKlebsiella pneumoniato imipenem, cefoperazone, cefoperazone sulbatam, piperacillin tazobactam, cefotaxime, cefotaxime, ceftazidime, ceftizoxime, gentamicin, ciprofloxacin, levofloxacin, aztreonam and ampicillin were significantly lower than those of the SS group and CS group (allP< 0.05). In patients of the RS group, the resistance rates ofPseudomonas aeruginosaandAcinetobacterto cefoperazone sulbatam, piperacillin tazobactam, cefotaxime, cefotaxime, ceftazidime, ceftizoxime, gentamicin, ciprofloxacin, levofloxacin, aztreonam and ampicillin were significantly lower than those of SS group and CS group (allP< 0.05).

Conclusions

The bacterial spectrum distribution of patients with diabetes combined with pulmonary infection of different clinical phenotypes were different. In view of the above infection characteristics, it is helpful to guide clinical antiinfection treatment.

Key words: Diabetes, Pulmonary infection, Clinical phenotype, Bacterial spectrum
表1 各组糖尿病合并肺部感染的菌谱特点（%）
组别 例数 菌株 细菌培养率 G+菌 G－菌 真菌 混合感染
RS组 55 50 95.00 20.00 76.00 4.00 4.00
SS组 70 79 100.00 69.60 25.30 5.10 11.39
CS组 83 103 100.00 33.90 59.30 6.80 19.41
χ2值 0.57 9.90 14.87 0.02 5.41
P值 0.09 0.001 0.001 0.60 0.01
表2 病原菌检测结果
病原菌 RS组 SS组 CS组
菌株 构成比（%） 菌株 构成比（%） 菌株 构成比（%）
G+球菌
肺炎链球菌 15 30.00 12 15.00 11 10.60
金黄色葡萄球菌 0 0.00 13 16.50 12 11.70
表皮葡萄球菌 0 0.00 10 12.70 4 3.90
草绿色链球菌 0 0.00 7 8.90 2 1.90
肠球菌 0 0.00 4 5.00 4 3.90
其他球菌 0 0.00 9 11.50 2 1.90
G－杆菌
肺炎克雷伯菌 18 36.00 8 10.10 32 31.00
铜绿假单胞杆菌 5 10.00 5 6.30 12 11.70
奇异变形杆菌 4 8.00 3 3.80 6 5.90
鲍曼/溶血不动杆菌 2 4.00 2 2.50 5 4.90
弗氏柠檬酸杆菌 2 4.00 1 1.30 3 2.90
不动杆菌 2 4.00 1 1.30 3 2.90
真菌
白色念珠菌 2 4.00 3 3.80 5 4.90
光滑球拟酵母菌 0 0.00 1 1.30 2 1.90
合计 50 100.00 79 100.00 103 100.00
表3 G+球菌耐药率（%）
抗菌药物 链球菌 葡萄球菌 肠球菌
RS（n = 15） SS（n = 19） CS（n = 15） χ2值 P值 RS（n = 0） SS（n = 23） CS（n = 16） χ2值 P值 RS（n = 0） SS（n = 4） CS（n = 4） χ2值 P值
庆大霉素 25.00 78.42 80.23 53.02 0.001 — 80.00 82.14 0.89 0.690 — 50.00 83.33 35.29 0.001
莫西沙星 1.22 7.23 6.24 4.42 0.040 — 20.00 16.34 4.34 0.040 — 28.00 45.00 15.24 0.002
万古霉素 0.00 0.00 0.00 0.65 0.810 — 0.00 0.00 1.06 0.460 — 0.00 0.00 0.63 0.180
利奈唑胺 0.00 0.00 0.00 0.96 0.760 — 0.00 0.00 2.01 0.330 — 0.00 0.00 0.52 0.210
左氧氟沙星 20.00 50.00 82.00 46.10 0.001 — 68.31 71.38 0.74 0.080 — 100.00 100.00 0.54 0.260
环丙沙星 16.00 56.00 65.00 15.86 0.001 — 70.10 70.89 0.82 0.130 — 100.00 100.00 0.59 0.300
克林霉素 25.00 52.00 73.00 4.30 0.030 — 48.85 53.09 5.88 0.040 — 98.32 100.00 0.68 0.070
四环素 50.00 48.00 79.00 10.91 0.010 — 75.76 100.00 9.89 0.010 — 100.00 100.00 0.62 0.430
阿奇霉素 14.00 42.00 58.00 28.87 0.001 — 50.91 72.78 9.65 0.010 — 100.00 85.00 6.25 0.010
利福平 78.65 89.80 92.30 9.35 0.002 — 100.00 100.00 0.90 0.240 — 100.00 100.00 0.58 0.480
青霉素 78.00 96.00 100.00 10.68 0.010 — 98.00 100.00 0.48 0.090 — 100.00 100.00 0.49 0.160
头孢呋辛 14.00 28.15 33.65 6.16 0.035 — 42.36 46.59 4.25 0.040 — 100.00 94.44 2.21 0.058
头孢唑肟 24.00 33.33 42.44 9.31 0.012 — 40.00 53.24 8.45 0.010 — 85.54 100 9.24 0.001
表4 G－杆菌的耐药率（%）
抗菌药物 肺炎克雷伯菌 铜绿假单胞杆菌和鲍曼/溶血不动杆菌
RS（n = 18） SS（n = 8） CS（n = 32） χ2值 P值 RS（n = 9） SS（n = 8） CS（n = 20） χ2值 P值
哌拉西林他唑巴坦 0.00 8.00 12.22 4.85 0.020 0.00 10.10 25.00 26.32 0.001
头孢他啶 3.89 20.00 33.33 53.74 0.001 2.24 25.00 42.16 37.09 0.001
头孢噻无 2.21 18.22 38.20 38.24 0.001 5.62 42.35 58.94 40.50 0.001
头孢哌酮舒巴坦 0.00 10.11 16.44 6.06 0.030 0.00 14.00 20.39 11.65 0.002
头孢吡肟 0.00 3.45 6.89 5.94 0.002 0.00 8.82 12.43 4.31 0.030
庆大霉素 25.00 52.86 68.00 7.47 0.001 20.00 50.00 68.00 9.42 0.003
亚胺培南 0.00 1.23 2.09 0.78 0.120 0.00 0.00 0.00 0.05 0.130
左氧氟沙星 50.00 75.00 90.00 23.90 0.003 75.00 92.86 100.00 8.60 0.010
环丙沙星 48.50 62.37 73.55 15.82 0.015 25.00 85.88 95.00 45.90 0.001
氨苄西林 58.00 76.88 82.89 19.04 0.001 75.00 92.33 100.00 14.26 0.001
头孢唑肟 12.50 61.55 72.43 25.14 0.001 15.70 57.85 66.90 33.50 0.001
氨曲南 37.50 52.63 57.14 9.88 0.022 25.00 63.97 85.71 24.81 0.001
[1]
Kuo IC, Lu PL, Lin WR, et al. Sphingomonas paucimobilis bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli[J].J Med Microbiol,2009,58(Pt9):1259-1263.
[2]
洪辉波，陈萍花，郭少君,等.抗菌药物的使用量与医院感染常见病原菌耐药性的相关性研究[J].中国药房,2010,21(42):3968-3971.
[3]
王玉巧，张跃斌，吴艳梅,等.细菌多药耐药的分子机制及研究进展[J].中国医师进修杂志(综合版),2008,31(5):70-73.
[4]
Holick MF. Vitamin D deficiency[J]. N EnglJ Med,2007,357(3):266-281.
[5]
Sabetta JR, DePetrillo P, Cipriani RJ, et al. Serum 25-hydroxyvita-min D and the incidence of acute viral respiratory tract infections in healthy adults[J]. PLoS One,2010,5(6):e11088.
[6]
Baeke F, Etten EV, Overberg L, et al. Vitamin D3 and immune system: maintaining the balance in health and disease[J]. Nutres Rev,2007,20(1):106-118.
[7]
Khaled A, Fazaa B, Ammar D, et al. Cutaneous, pulmonary and sinusal aspergillosis in a diabetic patient[J]. Tunis Med,2010,88(7):519-522.
[8]
林碧君，毛炳云.血培养阳性标本病原菌分布及耐药性分析[J].中国卫生检验杂志,2010,20(11):2923-2924.
[9]
Molbak K. The past decade’s infectious diseases[J].UgeskrLaeger,2011,173(6):414-416.
[10]
Clinical and ladmralory Standards Inslilute. Performance Standards for anti-mierobial susceptibility testing: twenty-second informational supplement[S]. CLSI [M100-S22]. 2012.
[11]
叶应妩，王毓三，申子瑜,等.全国临床检验操作规程[M]. 3版.北京:中华人民共和国医政司,2006:638-643.
[12]
World Health Organisation. Definition, diagbnosis and classification of diabetes mellitus and its complication. Report of a WHO consultation. Part 1: diagbnosis and classification of diabetes mellitus[M]. Geneva: World Health Oaganisation. 1999.
[13]
中华医学会呼吸病学分会.医院获得性肺炎的诊断和治疗指南(草案)[J].中华结核和呼吸杂志,1999,22(4):201-207.
[14]
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in china[J]. N Engl J Med,362(12):1090-1010.
[15]
JJeon CY, Furuya EY, Smaldone A, et al. Post-admission glucose levels are associated with healthcare-associated bloodstream infections and pneumonia in hospitalized patients with diabetes[J]. J Diabetes Complications,2012,26(6):517-521.
[16]
Zykova SN, Svartherg J, Seljelid R, et al. Release of TNF-alpha from in vitro-stimulate monocytes is negatively associated with serum levels of apolipoprote in B in patients with type 2 diabetes[J]. Scand J Immunol,2004,60(5):535-542.
[17]
Otton R, Soriano FG, Verlengia R, et al. Diabetes induces apoptosis in lymphocytes[J]. J Endocrinol,2004,182(1):145-156.
[18]
Matsunaga T, Nakajima T, Miyazaki T, et al. Glycated high density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells[J]. Metabolism,2003,52(1):42-49.
[19]
Song Y, Wang L, Pittas AG, et al. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies[J]. Diabetes Care,2013,36(5):1422-1428.
[20]
Terrier B, Derian N, Schoindre Y, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis insystemic lupus erythematosus patients through vitamin D supplementation[J]. Arthritis Res Ther,2012,14(5):R221.
[21]
Vimaleswaran KS, Berry DJ, Lu C, et al.Causal relationship between obesity and vitamin D status: bidirectional Mendelian randomization analysis of multiple cohorts[J]. PLoS Med,2013,10(2):e1001383.
[22]
Santos RD, Vianna LM. Effect of cholecalciferol supplementation on blood glucose in an experimental model of type 2 diabetesmellitus in spontaneously hypertentive rats and Wistar rats[J]. Clin Chim Acta,2005,358(1-2):146-150.
[23]
Yang J, Chen GH, Wang HB. Discussion on ameliorate the pancreatic islet-cell function in treatment with diabetes[J]. Chin J Curr Clin Med,2009,7(12):1093-1096.
[24]
Tahrani AA, Ball A, Shepherd L, et al. The prevalence of vitamin D abnormalities in South Asians with type 2 diabetes mellitus in the UK[J]. Int J Clin Pract,2010,64(3):351-355.
[25]
周广举，任伶俐，张园园,等. 2型糖尿病患者肺部感染病原菌分布及药物敏感性分析[J].中华医院感染学杂志,2014,24(18):4442-4444.
[26]
Ledizet M, Murray TS, Puttagunta S, et al. The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients[J]. PLoS One,2012,7(11):e49578.
[27]
李家泰，杨敏，WeinsteinAllan J,等.中国细菌耐药监测研究[J].中华医学杂志,2001,81(1):8-10.
[28]
刁学廉，廖军，萧正华,等.糖尿病合并肺部感染时免疫功能改变及防治感染的重要性[J].中华内分泌代谢杂志,2000,16(5):288-291.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(09): 872-876.
[2] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(07): 709-717.
[3] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[4] 徐志刚, 曹涛, 何亭, 李博奥, 魏婧韬, 张栋梁, 官浩, 杨薛康. 采用抗生素骨水泥治疗糖尿病患者心脏术后胸骨骨髓炎的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 498-502.
[5] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[6] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[7] 董大红, 周明虎, 李芝朋, 许正峰. 碳青霉烯类抗生素联合呼吸机治疗肺部感染的临床疗效分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 793-796.
[8] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[9] 周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[10] 杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[11] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[12] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[13] 李玺, 蔡芸莹, 张永红, 苏恒. 假性软骨发育不全合并1型糖尿病一例[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 518-520.
[14] 王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.
[15] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号